6. Global Influenza Vaccines Market Share and Y-o-Y Growth (%)
6.1 Number of Persons Vaccinated with Influenza Vaccines Share, 2018 - 2032 (%)
6.2 Influenza Vaccines Market Share, 2018 - 2032(%)
7. Global Influenza Vaccines Market Drivers and Challenges
7.1 Market Drivers
7.2 Market Challenges
8. Global Influenza Vaccines Market, By Geography (Volume and Value), 2018 - 2032
8.1 United States
8.1.1 United States Number of Persons Vaccinated with Influenza Vaccines (2015 - 2027)
8.1.2 United States Influenza Vaccines Market Revenue (2018 - 2032)
8.2 Canada
8.2.1 Canada Number of Persons Vaccinated with Influenza Vaccines (2015 - 2027)
8.2.2 Canada Influenza Vaccines Market Revenue (2018 - 2032)
8.3 Germany
8.3.1 Germany Number of Persons Vaccinated with Influenza Vaccines (2015 - 2027)
8.3.2 Germany Influenza Vaccines Market Revenue (2018 - 2032)
8.4 France
8.4.1 France Number of Persons Vaccinated with Influenza Vaccines (2015 - 2027)
8.4.2 France Influenza Vaccines Market Revenue (2018 - 2032)
8.5 Italy
8.5.1 Italy Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.5.2 Italy Influenza Vaccines Market Revenue (2018 - 2032)
8.6 Spain
8.6.1 Spain Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.6.2 Spain Influenza Vaccines Market Revenue (2018 - 2032)
8.7 United Kingdom
8.7.1 United Kingdom Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.7.2 United Kingdom Influenza Vaccines Market Revenue (2018 - 2032)
8.8 Netherlands
8.8.1 Netherlands Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.8.2 Netherlands Influenza Vaccines Market Revenue (2015 - 2027)
8.9 Sweden
8.9.1 Sweden Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.9.2 Sweden Influenza Vaccines Market Revenue (2018 - 2032)
8.10 Denmark
8.10.1 Denmark Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.10.2 Denmark Influenza Vaccines Market Revenue (2018 - 2032)
8.11 Poland
8.11.1 Poland Number of Persons Vaccinated with Influenza Vaccines (2015 - 2027)
8.11.2 Poland Influenza Vaccines Market Revenue (2018 - 2032)
8.12 Norway
8.12.1 Norway Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.12.2 Norway Influenza Vaccines Market Revenue (2018 - 2032)
8.13 Finland
8.13.1 Finland Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032 )
8.13.2 Finland Influenza Vaccines Market Revenue (2018 - 2032)
8.14 Ireland
8.14.1 Ireland Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.14.2 Ireland Influenza Vaccines Market Revenue (2018 - 2032) 110
8.15 Belgium
8.15.1 Belgium Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.15.2 Belgium Influenza Vaccines Market Revenue (2015 - 2027)
8.16 Australia
8.16.1 Australia Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.16.2 Australia Influenza Vaccines Market Revenue (2018 - 2032)
8.17 New Zealand
8.17.1 New Zealand Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.17.2 New Zealand Influenza Vaccines Market Revenue (2018 - 2032)
8.18 Japan
8.18.1 Japan Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.18.2 Japan Influenza Vaccines Market Revenue (2018 - 2032)
8.19 Brazil
8.19.1 Brazil Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.19.2 Brazil Influenza Vaccines Market Revenue (2018 - 2032)
8.20 China
8.20.1 China Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.20.2 China Influenza Vaccines Market Revenue (2018 - 2032)
8.21 India
8.21.1 India Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.21.2 India Influenza Vaccines Market Revenue (2018 - 2032)
8.22 South Korea
8.22.1 South Korea Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.22.2 South Korea Influenza Vaccines Market Revenue (2018 - 2032)
8.23 Thailand
8.23.1 Thailand Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.23.2 Thailand Influenza Vaccines Market Revenue (2018 - 2032)
8.24 Singapore
8.24.1 Singapore Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.24.2 Singapore Influenza Vaccines Market Revenue (2018 - 2032)
8.25 Hongkong
8.25.1 Hongkong Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.25.2 Hongkong Influenza Vaccines Market Revenue (2018 - 2032)
8.26 Malaysia
8.26.1 Malaysia Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.26.2 Malaysia Influenza Vaccines Market Revenue (2018 - 2032)
8.27 Indonesia
8.27.1 Indonesia Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.27.2 Indonesia Influenza Vaccines Market Revenue (2018 - 2032)
8.28 Rest of the World (ROW)
8.28.1 ROW Number of Persons Vaccinated with Influenza Vaccines (2018 - 2032)
8.28.2 ROW Influenza Vaccines Market Revenue (2018 - 2032)
10. Regulatory Framework of the Global Influenza Vaccines Market
10.1 United States
10.2 Europe
10.3 Japan
11. Major Deals in the Global Influenza Vaccines Market
11.1 Merger and Acquisitions
11.2 Collaboration Deals
11.3 Licensing Agreement
11.4 Exclusive Agreement
11.5 Distribution Agreement
12. Influenza Vaccines Clinical Trial Insights by Phase, Company & Country
12.1 Year 2023
12.2 Year 2022
13. Key Companies Analysis
13.1 Sanofi Pasteur
13.1.1 Business Overview
13.1.2 Influenza Vaccines Portfolio
13.1.3 Influenza Vaccines Value Sales Analysis
13.1.4 Promising Influenza Vaccines in the Clinical Development
13.1.5 Recent Development
13.2 GlaxoSmithKline (GSK)
13.2.1 Business Overview
13.2.2 Influenza Vaccines Portfolio
13.2.3 Influenza Vaccines Sales Value Analysis
13.2.4 Recent Development
13.3 Seqirus (CSL Limited)
13.3.1 Business Overview
13.3.2 Influenza Vaccines Portfolios
13.3.3 Influenza Vaccines Sales Value Analysis
13.3.4 Promising Influenza Vaccines in the Clinical Development
13.3.5 Recent Development
13.4 AstraZeneca
13.4.1 Business Overview
13.4.2 Influenza Vaccines Portfolio
13.4.3 Influenza Vaccines Sales Value Analysis
13.4.4 Recent Development
13.5 Gamma Vaccines Pty Ltd
13.5.1 Business Overview
13.5.2 Influenza Vaccines Portfolio
13.5.3 Recent Development
13.6 Hualan Biological Engineering Inc
13.6.1 Business Overview
13.6.2 Influenza Vaccines Portfolio
13.6.3 Recent Development
13.7 Shanghai Institute of Biological Products Co., Ltd.
13.7.1 Business Overview
13.7.2 Influenza Vaccines Portfolio
13.7.3 Recent Development
13.8 Mylan
13.8.1 Business Overview
13.8.2 Influenza Vaccines Portfolio
13.8.3 Recent Development
13.9 BioDiem
13.9.1 Business Overview
13.9.2 Influenza Vaccines Portfolio
13.9.3 Recent Development
13.10 BIKEN Co., Ltd.
13.10.1 Business Overview
13.10.2 Influenza Vaccine Portfolio
13.10.3 Recent Development
14. Emerging Players
14.1 Novavax
14.1.1 Business Overview
14.1.2 Promising Influenza Vaccines in the Clinical Development
14.1.3 Recent Development
14.2 BiondVax Pharmaceuticals Ltd.
14.2.1 Business Overview
14.2.2 Promising Influenza Vaccines in the Clinical Development
14.2.3 Recent Development
14.3 Medicago
14.3.1 Business Overview
14.3.2 Promising Influenza Vaccines in the Clinical Development
14.3.3 Recent Development
14.4 Moderna Inc
14.4.1 Business Overview
14.4.2 Promising Influenza Vaccines in the Clinical Development
14.4.3 Recent Development
14.5 Pneumagen
14.5.1 Business Overview
14.5.2 Promising Influenza Vaccines in the Clinical Development
14.5.3 Recent Development
14.6 Altimmune
14.6.1 Business Overview
14.6.2 Promising Influenza Vaccines in the Clinical Development
14.6.3 Recent Development
14.7 Daiichi Sankyo
14.7.1 Business Overview
14.7.2 Promising Influenza Vaccines in the Clinical Development
14.7.3 Recent Development
14.8 FluGen
14.8.1 Business Overview
14.8.2 Promising Influenza Vaccines in the Clinical Development
14.8.3 Recent Development
14.9 Imutex
14.9.1 Business Overview
14.9.2 Promising Vaccines in the Clinical Development
14.9.3 Recent Development
14.10 EpiVax
14.10.1 Business Overview
14.10.2 Promising Influenza Vaccines in the Clinical Development
14.10.3 Recent Development
14.11 Versatope Therapeutics, Inc.
14.11.1 Business Overview
14.11.2 Promising Influenza Vaccines in the Clinical Development
14.11.3 Recent Development
14.12 Emergex Vaccines
14.12.1 Business Overview
14.12.2 Promising Influenza Vaccines in the Clinical Development
14.12.3 Recent Development
14.13 Osivax
14.13.1 Business Overview
14.13.2 Promising Influenza Vaccines in the Clinical Development
14.13.3 Recent Development
15. Appendix
15.1 About the Publisher
15.2 Glossary of Terms
List of Tables
Table 6-1: Global Number of Persons Vaccinated with Influenza Vaccines Share (Percent), 2018 - 2032
Table 6-2: Global Number of Persons Vaccinated with Influenza Vaccines Share Forecast (Percent), 2024 - 2032
Table 6-3: Global Influenza Vaccines Market Share (Percent), 2018 - 2023
Table 6-4: Global Influenza Vaccines Market Share Forecast (Percent), 2023 - 2032
Table 10-1: United States - Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 10-2: European Union - Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 10-3: Japan - Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 11-1: Merger & Acquisitions in the Influenza Vaccines Market
Table 11-2: Collaboration Deal in the Influenza Vaccines Market
Table 11-3: Licensing Agreement in the Influenza Vaccines Market
Table 11-4: Exclusive Agreement in the Influenza Vaccines Market
Table 11-5: Distribution Agreement in the Influenza Vaccines Market
Table 13-1: Sanofi Pasteur Promising Influenza Vaccines in the Clinical Development
Table 13-2: Seqirus Promising Influenza Vaccines in the Clinical Development
Table 14-1: Novavax Promising Influenza Vaccines in the Clinical Development
Table 14-2: Biondvax Promising Influenza Vaccines in the Clinical Development
Table 14-3: Medicago Promising Influenza Vaccines in the Clinical Development
Table 14-4: Moderna Promising Influenza Vaccines in the Clinical Development
Table 14-5: Pneumagen Promising Influenza Vaccines in the Clinical Development
Table 14-6: Altimmune Promising Influenza Vaccines in the Clinical Development
Table 14-7: Daiichi Sankyo Promising Influenza Vaccines in the Clinical Development
Table 14-8: FluGen Promising Influenza Vaccines in the Clinical Development
Table 14-9: Imutex Promising Influenza Vaccines in the Clinical Development
Table 14-10: EpiVax Promising Influenza Vaccines in the Clinical Development
Table 14-11: Versatope Therapeutics, Inc. Promising Influenza Vaccines in the Clinical Development
List of Figures
Figure 4-1: Global Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 4-2: Global Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 5-1: Global Influenza Vaccines Market (Million US$), 2018 - 2023
Figure 5-2: Global Influenza Vaccines Market Forecast (Million US$), 2024 - 2032
Figure 8-1: United States Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-2: United States Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-3: United States Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-4: United States Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-5: Canada Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-6: Canada Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-7: Canada Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-8: Canada Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-9: Germany Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-10: Germany Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-11: Germany Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-12: Germany Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-13: France Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-14: France Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-15: France Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-16: France Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-17: Italy Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-18: Italy Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-19: Italy Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-20: Italy Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-21: Spain Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-22: Spain Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-23: Spain Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-24: Spain Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-25: United Kingdom Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-26: United Kingdom Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-27: United Kingdom Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-28: United Kingdom Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-29: Netherlands Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-30: Netherlands Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-31: Netherlands Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-32: Netherlands Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-33: Sweden Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-34: Sweden Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-35: Sweden Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-36: Sweden Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-37: Denmark Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-38: Denmark Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-39: Denmark Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-40: Denmark Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-41: Poland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-42: Poland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-43: Poland Influenza Vaccines Revenue Market (Million US$), 2018 - 2023
Figure 8-44: Poland Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-45: Norway Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-46: Norway Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-47: Norway Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-48: Norway Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-49: Finland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-50: Finland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-51: Finland Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-52: Finland Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-53: Ireland Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-54: Ireland Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-55: Ireland Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-56: Ireland Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-57: Belgium Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-58: Belgium Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-59: Belgium Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-60: Belgium Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-61: Australia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-62: Australia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-63: Australia Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-64: Australia Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-65: New Zealand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-66: New Zealand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-67: New Zealand Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-68: New Zealand Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-69: Japan Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-70: Japan Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-71: Japan Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-72: Japan Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-73: Brazil Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-74: Brazil Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2023 - 2032
Figure 8-75: Brazil Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-76: Brazil Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8 77: China Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-78: China Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-79: China Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-80: China Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-81: India Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-82: India Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-83: India Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-84: India Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-85: South Korea Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-86: South Korea Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-87: South Korea Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-88: South Korea Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-89: Thailand Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-90: Thailand Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-91: Thailand Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-92: Thailand Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-93: Singapore Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-94: Singapore Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-95: Singapore Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-96: Singapore Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-97: Hongkong Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-98: Hongkong Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-99: Hongkong Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-100: Hongkong Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-101: Malaysia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-102: Malaysia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-103: Malaysia Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-104: Malaysia Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-105: Indonesia Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-106: Indonesia Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-107: Indonesia Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-108: Indonesia Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 8-109: ROW Number of Persons Vaccinated with Influenza Vaccines (Thousand), 2018 - 2023
Figure 8-110: ROW Number of Persons Vaccinated with Influenza Vaccines Forecast (Thousand), 2024 - 2032
Figure 8-111: ROW Influenza Vaccines Market Revenue (Million US$), 2018 - 2023
Figure 8-112: ROW Influenza Vaccines Market Revenue Forecast (Million US$), 2024 - 2032
Figure 13-1: Sanofi Pasteur Influenza Vaccines Net Sales Value (Million US$), 2018 - 2023
Figure 13-2: Sanofi Pasteur Influenza Vaccines Net Sales Value Forecast (Million US$), 2024 - 2032
Figure 13-3: GSK Influenza Vaccines Net Sales Value (Million US$), 2018 - 2023
Figure 13-4: GSK Influenza Vaccines Net Sales Value Forecast (Million US$), 2024 - 2032
Figure 13-5: Seqirus Influenza Vaccines Net Sales Value (Million US$), 2018 - 2023
Figure 13-6: Seqirus Influenza Vaccines Net Sales Value Forecast (Million US$), 2024 - 2032
Figure 13-7: AstraZeneca Influenza Vaccines Net Sales Value (Million US$), 2018 - 2023
Figure 13-8: AstraZeneca Influenza Vaccines Net Sales Value Forecast (Million US$), 2024 - 2032